FORT COLLINS, Colo.,
Aug. 31, 2021 /PRNewswire/ --
Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical
company creating next-generation immune therapies that focus
on immune restoration and homeostasis, today announced plans
to change its corporate name to "Statera BioPharma, Inc." and
update its ticker symbol to "STAB" effective Wednesday, September 1, 2021. As part of the name
change, Statera BioPharma (NASDAQ: STAB) plans to release a new
company logo and launch a new company website at
www.staterabiopharma.com. The new corporate name, Statera,
taken from the Latin word for "balance," and tagline "Restoring
Immune Health" was chosen to better reflect the company's strategic
focus on addressing autoimmune and inflammatory diseases, blood
disorders, infectious disease and cancer.
Cytocom, Inc. emerged as a publicly-traded entity following the
merger between the former Cleveland BioLabs and the formerly
private Cytocom Inc., completed on July 27,
2021.
"The new corporate name, Statera BioPharma and updated ticker
symbol mark the latest event in a transformative year for the
company," said Michael K. Handley,
President and CEO of Cytocom. "The completion of the recent merger
transaction brought together two companies and promising technology
platforms to create a potential powerhouse in the immune modulation
field with one of the largest pipelines of toll-like immune
receptors in the biopharmaceuticals industry. Our new name
emphasizes the work underway as we advance our late-stage clinical
assets that are designed to restore immune health."
About Cytocom
Cytocom, Inc. is a
clinical-stage biopharmaceutical company developing novel
immunotherapies targeting autoimmune, neutropenia/anemia, emerging
viruses and cancers based on a proprietary platform designed to
rebalance the body's immune system and restore homeostasis. The
company also has one of the largest platforms of toll-like
receptors (TLR4, TLR5 and TLR9) in the biopharmaceutical industry,
addressing conditions such as radiation sickness and cancer
treatment side effects. Cytocom is developing
therapies designed to elicit directly within patients a robust and
durable response of antigen-specific killer T-cells and antibodies,
thereby activating essential immune defenses against autoimmune,
inflammatory, infectious diseases, and cancers.
Specifically, Cytocom has several clinical-stage
development programs for Crohn's disease, hematology, pancreatic
cancer, and COVID-19 in addition to expansion to fibromyalgia and
multiple sclerosis. To learn more about Cytocom, Inc.,
please visit www.cytocom.com.
Forward Looking Statements
This press release
contains forward-looking statements that involve risks and
uncertainties. All statements other than statements of current or
historical fact contained in this press release, including
statements regarding the Company's expected clinical development
timeline for the Company's product candidates, future financial
position, business strategy, new products, budgets, liquidity, cash
flows, projected costs, regulatory approvals, the impact of any
laws or regulations applicable to the company, and plans and
objectives of management for future operations, are forward-looking
statements. The words "anticipate," "believe," "continue,"
"should," "estimate," "expect," "intend," "may," "plan," "project,"
"will," and similar expressions, as they relate to us, are intended
to identify forward-looking statements. We have based these
forward-looking statements on the current expectations about future
events held by management. While we believe these expectations are
reasonable, such forward-looking statements are inherently subject
to risks and uncertainties, many of which are beyond the Company's
control. The company's actual future results may differ materially
from those discussed here for various reasons. The Company
discusses many of these risks under the heading "Risk Factors" in
the proxy statement/prospectus filed with the SEC on June 10, 2021, as updated by the company's other
filings with the SEC. Factors that may cause such differences
include, but are not limited to, the outcome of any legal
proceedings that have been or may be instituted against the company
related to the merger between Cleveland BioLabs and Cytocom;
unexpected costs, charges or expenses resulting from the merger;
the Company's need for additional financing to meet the Company's
business objectives; the Company's history of operating losses; the
Company's ability to successfully develop, obtain regulatory
approval for, and commercialize the Company's products in a timely
manner; the Company's plans to research, develop and commercialize
the Company's product candidates; the Company's ability to attract
collaborators with development, regulatory and commercialization
expertise; the Company's plans and expectations with respect to
future clinical trials and commercial scale-up activities; the
Company's reliance on third-party manufacturers of the Company's
product candidates; the size and growth potential of the markets
for the Company's product candidates, and the Company's ability to
serve those markets; the rate and degree of market acceptance of
the Company's product candidates; regulatory requirements and
developments in the United States,
the European Union and foreign countries; the performance of the
Company's third-party suppliers and manufacturers; the success of
competing therapies that are or may become available; the Company's
ability to attract and retain key scientific or management
personnel; the Company's historical reliance on government funding
for a significant portion of the Company's operating costs and
expenses; government contracting processes and requirements; the
exercise of significant influence over the Company's company by the
Company's largest individual stockholder; the impact of the novel
coronavirus ("COVID-19") pandemic on the Company's business,
operations and clinical development; the geopolitical relationship
between the United States and the
Russian Federation as well as
general business, legal, financial and other conditions within the
Russian Federation; the Company's
ability to obtain and maintain intellectual property protection for
the Company's product candidates; the Company's potential
vulnerability to cybersecurity breaches; and other factors
discussed in the Company's SEC filings, including the Company's
Annual Report on Form 10-K for the year ended December 31, 2020 and the risk factors discussed
under the heading "Risk Factors" in the proxy statement/prospectus
the company filed in connection with the merger on June 10, 2021.
Given these uncertainties, you should not place undue
reliance on these forward-looking statements. The forward-looking
statements included in this press release are made only as of the
date hereof. We do not undertake any obligation to update any such
statements or to publicly announce the results of any revisions to
any of such statements to reflect future events or
developments.
Contacts:
Cytocom, Inc.
Nichol Ochsner
Senior V.P. Investor Relations and Corporate Communications
(732) 754-2545
nichol.ochsner@cytocom.com
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA
(Investors)
(212) 375-2664
mmcenroe@tiberend.com
Johanna Bennett (Media)
(212) 375-2686
Jbennett@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytocom-inc-announces-plan-to-adopt-new-corporate-name-statera-biopharma-inc-301365657.html
SOURCE Cytocom, Inc.